Evidence map›Paper›PMID 24013960›Full record

ArticleGlycobiology2013

Utilization of major fucosylated and sialylated human milk oligosaccharides by isolated human gut microbes.

Zhuo-Teng Yu, Ceng Chen, David S Newburg

Open access · bronzeAbstract read
In one paragraph

Article in Glycobiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 209 papers.

0numbers the graph read from it
0cells of the map it votes in
209citing papers in PubMed
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

209 citing papers in PubMed, 379 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. A bidirectionalbioRxiv : the preprint server for biology · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Synbiotic effects of 2'-fucosyllactose andFrontiers in nutrition · 2026
    Article
  20. Review

149 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Zhuo-Teng YuDepartment of Biology, Boston College, Chestnut Hill, MA 02467, USA.
Ceng Chen
David S Newburg
Boston College · US

Funding

VIRAL GASTROENTERITIS PATHOGENSP01HD013021 · NICHD · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MORROW, ARDYTHE L · 1985 to 2013
$15.0M
Novel broad spectrum therapeutic glycans against Category B pathogensU01AI075563 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI NEWBURG, DAVID S. · 2007 to 2011
$4.5M
Novel genetic and salivary glycan biomarkers for risk of NEC in ELBW infants.R01HD059140 · NICHD · CINCINNATI CHILDRENS HOSP MED CTR · PI MORROW, ARDYTHE L · 2009 to 2013
$3.3M
NIAID NIH HHS NIH AI075563NICHD NIH HHS HD013021NICHD NIH HHS HD059140
6 · The paper itself

Abstract

Human milk oligosaccharides (HMOS) are not digested in the proximal intestine. In distal intestine, HMOS collectively modify the microbiota, but the response of individual bacteria to individual components of the HMOS is not well defined. Here, each of 25 major isolates of the human intestinal microbiota was fed individual major fucosylated and sialylated HMOS in anaerobic culture. This allowed for an assessment of the influence of specific HMOS on the growth and metabolic products of individual microbiota bacteria. Most Bifidobacteria spp. and Bacteroides spp. grew, induced α-L-fucosidase activity, and produced abundant lactate or short-chain fatty acids (SCFAs) when fed 2'-fucosyllactose (2'-FL), 3-FL, and lactodifucotetraose (LDFT). Lactobacillus delbrueckii ATCC7830, Enterococcus faecalis ATCC19433, and Streptococcus thermophilus ATCC19258 exhibited slight growth, pH reduction, and lactate production when supplemented with 2'-FL or 3-FL, but not LDFT. Supplementation with 3'-sialyllactose (3'-SL) and 6'-SL promoted moderate growth of Bifidobacterium longum JCM7007, 7009, 7010, 7011, 1272, 11347, ATCC15708, Bacteroides vulgatus ATCC8482, and B. thetaiotaomicron ATCC29148; accordingly, these bacteria exhibited greater neuraminidase activity and produced copious lactate, SCFA, or both. Lactobacillus delbrueckii ATCC7830 also consumed 6'-SL. In contrast, Clostridium spp., L. rhamnosus ATCC53103, E. faecalis ATCC29200, Staphylococcus spp., Enterobacter spp., and Escherichia coli K12 did not consume milk oligosaccharides nor produce appreciable acidic fermentation products. Specific Bifidobacteria and Bacteroides differentially digest specific individual HMOS, with the major fucosylated milk oligosaccharides most strongly stimulating key species of mutualist symbionts. This suggests strategies for treating dysbiosis of the microbiota and associated inflammatory disorders.

Indexed as

Microbiotaalpha-L-FucosidaseBacterial ProteinsBacteroidesBifidobacteriumClostridiumCulture MediaEnterococcus faecalisEscherichia coli K12FucoseGastrointestinal TractGlycosylationHumansHydrogen-Ion ConcentrationLactobacillus delbrueckiiMilk, Humanalpha-L-FucosidaseBacterial ProteinsCulture MediaFucoseOligosaccharidesSialic Acidscommensal bacteriaglycosidasehuman milk oligosaccharidesmutualist bacteriaorganic acids

Identifiers

PMID24013960
PMCPMC3796377
OpenAlexW2169677770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.